Explain this page
Arphra AIPlain-English read on Bio-Rad Laboratories, Inc.’s valuation06-04today
- Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 20267h
- Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 20267h
- Silexion Therapeutics to Attend BIO International Convention 202622h
- Silexion Therapeutics to Attend BIO International Convention 202622h
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$259.82
-10.97% vs spot
Recommendation
Underweight
16 of 17 methods
Method spread
2bull10bear
±5% threshold
Analyst PT consensus: $321.67 (+10.23%)
Candlestick · 1Y
Open in chart workstation →BIO
289.28-2.74%H 319.86L 236.73MA50 276.79MA200 —Avg vol 353K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.65% | -0.59% | +17.90% | +8.29% | -3.14% | -3.68% | +26.63% | -21.29% | -52.75% | +107.09% | +11360.96% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$291.83
840 sh
Bid
$290.06
120 sh
Ask
$294.06
80 sh
Spread
$4.000
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $592.1M | -$527.1M | $-19.55 |
| Q4 Dec 2025 | $693.2M | $720M | $26.65 |
| Q3 Sep 2025 | $653M | -$341.9M | $-12.70 |
| Q2 Jun 2025 | $651.6M | $317.8M | $11.67 |
| Q1 Mar 2025 | $585.4M | $64M | $2.29 |
| Q4 Dec 2024 | $667.48M | -$715.8M | $-25.57 |
Sector & industry today
LiveSectors
- Industrials+1.07%
- Basic Materials+0.91%
- Consumer Cyclical+0.86%
- Utilities+0.40%
- Financial Services+0.17%
- Healthcare-0.25%
- Real Estate-0.30%
- Technology-0.35%
- Energy-0.43%
- Consumer Defensive-0.52%
- Communication Services-0.74%
Top industries (issuer's industry highlighted)
- Medical - Devices+0.38%
- Biotechnology-4.48%
- Communication Equipment-2.96%
- Agricultural - Machinery+2.04%
- Internet Content & Information-1.67%
- Agricultural Inputs+1.63%
- Software - Application-1.63%
- Software - Infrastructure-1.60%
- Computer Hardware-1.54%
- Travel Services+1.49%
- Furnishings, Fixtures & Appliances+1.48%
- Grocery Stores-1.47%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026globenewswire.com·Jun 17, 2026
- Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026globenewswire.com·Jun 17, 2026
- Silexion Therapeutics to Attend BIO International Convention 2026globenewswire.com·Jun 16, 2026
- Silexion Therapeutics to Attend BIO International Convention 2026globenewswire.com·Jun 16, 2026
- Enveric Biosciences Announces Participation in 2026 BIO International Conventionbusinesswire.com·Jun 16, 2026
- Enveric Biosciences Announces Participation in 2026 BIO International Conventionbusinesswire.com·Jun 16, 2026
- Neurophet Showcases 'Brain Imaging AI Solutions' at BIO USA, Accelerates Global Business Development Collaborationsprnewswire.com·Jun 16, 2026
- Neurophet Showcases 'Brain Imaging AI Solutions' at BIO USA, Accelerates Global Business Development Collaborationsprnewswire.com·Jun 16, 2026
Peers
No peer list available for BIO.
Total assets
$10.58B
Total debt
$1.53B
Cash & equiv
$531.8M
Operating CF
$532.2M
Free cash flow
$374.6M
Buybacks
-$295.5M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $2.58B | $270.5M | $759.9M | $27.87 | +29.42% |
| FY 2024 | $2.57B | $269M | -$1.84B | $-65.36 | -71.86% |
| FY 2023 | $2.67B | $337.8M | -$637.32M | $-21.82 | -23.86% |
| FY 2022 | $2.8B | $482.62M | -$3.63B | $-121.79 | -129.45% |
| FY 2021 | $2.92B | $500.34M | $4.25B | $140.83 | +145.57% |